10.5 months; HR 0.52) in pretreated NSCLC with prior CNS disease (CodeBreaK200 phase III trial) [ 52 ], although these results did not reach statistical significance.
← all excerpts
Preventive strategies against brain metastases: current state of the art and future directions.
1
—
—